Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3198688 | 0.94 | GNAI3 (0.36) | KMT2AALDH1A1MEN1SMN1; SMN2BRD4 | |
| Fumaric Acid SCHEMBL3220938 | 0.79 | HTR1A (0.42) | KMT2AALDH1A1MEN1SMN1; SMN2KDM4E | |
| Fumaric Acid SCHEMBL3220918 | 0.79 | HTR1A (0.42) | KMT2AALDH1A1MEN1SMN1; SMN2KDM4E | |
| SCHEMBL4717253 | 0.79 | HTR6 (0.44) | DRD2DRD4 | |
| SCHEMBL15914294 | 0.79 | MEN1 (0.39) | KMT2AALDH1A1MEN1SMN1; SMN2KDM4E | |
| SCHEMBL4714296 | 0.77 | KDM4E (0.47) | KMT2AALDH1A1MEN1KDM4EALOX15 | |
| Fumaric Acid SCHEMBL3221298 | 0.76 | KDM4E (0.48) | KMT2AALDH1A1MEN1KDM4EALOX15 | |
| Fumaric Acid SCHEMBL3221286 | 0.76 | KDM4E (0.48) | KMT2AALDH1A1MEN1KDM4EALOX15 | |
| SCHEMBL3207054 | 0.76 | MEN1 (0.36) | KMT2AALDH1A1MEN1SMN1; SMN2BRD4 | |
| SCHEMBL3220411 | 0.75 | GNAI3 (0.47) | ALDH1A1KDM4EDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | KMT2A 3808/4885ALDH1A1 1897/4885MEN1 2777/4885 |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | KMT2A 3808/4885ALDH1A1 1897/4885MEN1 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.